SCHEMBL5845117

SCHEMBL5845117

NCCC(O)Cc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.48
HRH1 P35367 1/20 0.46
TRPA1 O75762 2/20 0.46
SRR Q9GZT4 2/20 0.46
ALPI P09923 1/20 0.45
PKM P14618 1/20 0.45
PTGS1 P23219 1/20 0.45
XIAP P98170 1/20 0.45
SLC7A5 Q01650 1/20 0.45
TAAR1 Q96RJ0 3/20 0.45
SLC6A2 P23975 2/20 0.45
CYP2A6 P11509 2/20 0.45
MAOA P21397 1/20 0.45
SLC6A4 P31645 1/20 0.45
SLC6A3 Q01959 1/20 0.45
SIGMAR1 Q99720 1/20 0.45
ADORA2A P29274 1/20 0.45
ADORA1 P30542 1/20 0.45
ALDH1A1 P00352 1/20 0.45
HTR2A P28223 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8357017 1.00 EPHX1 (0.48) EPHX1HRH1TRPA1SRRALPI
SCHEMBL8356053 1.00 EPHX1 (0.48) EPHX1HRH1TRPA1SRRALPI
SCHEMBL8643652 0.88 HTR2A (0.50) EPHX1HRH1TRPA1SRRALPI
SCHEMBL5105980 0.86 TRPA1 (0.52) EPHX1TRPA1SRRALPIPKM
SCHEMBL5678777 0.82 EPHX1 (0.52) EPHX1TRPA1SRRALPIPKM
SCHEMBL7472546 0.82 EPHX1 (0.52) EPHX1TRPA1SRRALPIPKM
SCHEMBL5097040 0.82 TRPA1 (0.48) EPHX1TRPA1SRRALPIPKM
SCHEMBL194646 0.82 EPHX1 (0.52) EPHX1TRPA1SRRALPIPKM
SCHEMBL1833635 0.81 TRPA1 (0.55) EPHX1TRPA1SRRALPIPKM
SCHEMBL6680790 0.81 HTR2A (0.54) HRH1TAAR1CYP2A6MAOAHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7012099-B2 Using substituted 4-amino-1- phenylbutan-2-ol compounds in form of their racemates, enantiomers, diastereoisomers or corresponding bases or corresponding salts of acids as regulators for the nociceptin/orphanin FQ ligands in drugs GRUENENTHAL GMBH (DE) 2006-03-14 US claimed
EP-1253917-B1 USE OF SUBSTITUTED 4-AMINO-1-PHENYLBUTAN-2-OL COMPOUNDS AS MEDICAMENTS GRUENENTHAL GMBH (DE) 2005-02-16 EP claimed
US-20030008859-A1 Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments GRUENENTHAL GMBH (DE) 2003-01-09 US claimed
EP-1253917-A2 USE OF SUBSTITUTED 4-AMINO-1-PHENYLBUTAN-2-OL COMPOUNDS AS MEDICAMENTS Grünenthal GmbH (DE) 2002-11-06 EP claimed
WO-2001047506-A2 USE OF SUBSTITUTED 4-AMINO-1-PHENYLBUTAN-2-OL COMPOUNDS AS MEDICAMENTS Grünenthal GmbH (DE) 2001-07-05 WO claimed
US-4522984-A WITH E-CAPROLACTONE DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1985-06-11 US claimed
CN-115677800-A Pseudomonas aeruginosa O10 serotype O-antigen trisaccharide and synthetic method thereof 山东大学 2023-02-03 CN disclosed
EP-3823628-A1 <SMALLCAPS/>? ? ?S? ? ? ? ?CERTAIN (2)- <NS1:I>N</NS1:I>?-[(1 <NS2:I>S</NS2:I>?)-1-CYANO-2-PHENYLETHYL]-1,4- OXAZEPANE-2-CARBOXAMIDES FOR TREATING INFLAMMATORY BOWEL DISEASE Insmed Incorporated (US) 2021-05-26 EP disclosed
EP-3823627-A1 CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING LUPUS NEPHRITIS Insmed Incorporated (US) 2021-05-26 EP disclosed
WO-2020018547-A1 CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING LUPUS NEPHRITIS INSMED INCORPORATED (US) 2020-01-23 WO disclosed
WO-2020018551-A1 CERTAIN (2S)- N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4- OXAZEPANE-2-CARBOXAMIDES FOR TREATING INFLAMMATORY BOWEL DISEASE INSMED INCORPORATED (US) 2020-01-23 WO disclosed
CN-110483492-A Dipeptidyl peptidase i inhibitors ASTRAZENECA AB 2019-11-22 CN disclosed
CN-105980367-B (2S) -N- [ (1S) -1-cyano-2-phenylethyl ] -1, 4-oxazepane-2-carboxamides as dipeptidyl peptidase I inhibitors 阿斯利康(瑞典)有限公司 2019-08-23 CN disclosed
WO-2001047506-A2 USE OF SUBSTITUTED 4-AMINO-1-PHENYLBUTAN-2-OL COMPOUNDS AS MEDICAMENTS Grünenthal GmbH (DE) 2001-07-05 WO disclosed
EP-0876381-A1 IFOSFAMIDE, ANALOGUES THEREOF AND THEIR PREPARATION Darwin Discovery Limited (GB) 1998-11-11 EP disclosed
WO-1998010286-A1 METHODS FOR PROCESSING CHEMICAL COMPOUNDS HAVING REACTIVE FUNCTIONAL GROUPS ISIS PHARMACEUTICALS, INC. (US) 1998-03-12 WO disclosed
WO-1998005961-A1 COMPOUNDS HAVING A PLURALITY OF NITROGENOUS SUBSTITUENTS ISIS PHARMACEUTICALS, INC. (US) 1998-02-12 WO disclosed
WO-1997022614-A1 IFOSFAMIDE, ANALOGUES THEREOF AND THEIR PREPARATION DARWIN DISCOVERY LIMITED (GB) 1997-06-26 WO disclosed
US-4522984-A WITH E-CAPROLACTONE DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1985-06-11 US disclosed
US-4521570-A Modified epoxy resin and composition DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1985-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030008859-A1 Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments OPRL1, OPRM1, OPRK1 EPHX1 1622/4885HRH1 224/4885TRPA1 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.